RU2230115C2 - Промотор гена человеческого эндоглина и его применение - Google Patents

Промотор гена человеческого эндоглина и его применение Download PDF

Info

Publication number
RU2230115C2
RU2230115C2 RU98101849/13A RU98101849A RU2230115C2 RU 2230115 C2 RU2230115 C2 RU 2230115C2 RU 98101849/13 A RU98101849/13 A RU 98101849/13A RU 98101849 A RU98101849 A RU 98101849A RU 2230115 C2 RU2230115 C2 RU 2230115C2
Authority
RU
Russia
Prior art keywords
promoter
gene
sequence
nucleotide construct
construct according
Prior art date
Application number
RU98101849/13A
Other languages
English (en)
Russian (ru)
Other versions
RU98101849A (ru
Inventor
Вольфф ГРАУЛИХ (DE)
Вольфф ГРАУЛИХ
Дирк НЕТТЕЛЬБЕК (DE)
Дирк НЕТТЕЛЬБЕК
Ханс-Харальд СЕДЛАЧЕК (DE)
Ханс-Харальд Седлачек
Рольф МЮЛЛЕР (DE)
Рольф Мюллер
Original Assignee
Авентис Фарма Дойчланд Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Авентис Фарма Дойчланд Гмбх filed Critical Авентис Фарма Дойчланд Гмбх
Publication of RU98101849A publication Critical patent/RU98101849A/ru
Application granted granted Critical
Publication of RU2230115C2 publication Critical patent/RU2230115C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
RU98101849/13A 1997-02-06 1998-02-05 Промотор гена человеческого эндоглина и его применение RU2230115C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19704301.1 1997-02-06
DE19704301A DE19704301C1 (de) 1997-02-06 1997-02-06 Der Promotor des humanen Endoglingens und seine Verwendung für die Gentherapie

Publications (2)

Publication Number Publication Date
RU98101849A RU98101849A (ru) 2000-02-20
RU2230115C2 true RU2230115C2 (ru) 2004-06-10

Family

ID=7819364

Family Applications (1)

Application Number Title Priority Date Filing Date
RU98101849/13A RU2230115C2 (ru) 1997-02-06 1998-02-05 Промотор гена человеческого эндоглина и его применение

Country Status (15)

Country Link
US (1) US6103527A (enExample)
EP (1) EP0857781A3 (enExample)
JP (1) JPH11178A (enExample)
KR (1) KR19980071084A (enExample)
CN (1) CN1196784C (enExample)
AR (1) AR011110A1 (enExample)
AU (1) AU736724B2 (enExample)
BR (1) BR9800563A (enExample)
CA (1) CA2222981A1 (enExample)
CZ (1) CZ289227B6 (enExample)
DE (1) DE19704301C1 (enExample)
HU (1) HUP9800247A3 (enExample)
PL (1) PL324688A1 (enExample)
RU (1) RU2230115C2 (enExample)
TR (1) TR199800168A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2295281C2 (ru) * 2005-04-20 2007-03-20 Федеральное государственное учреждение Научно-исследовательский институт детских инфекций, г.Санкт-Петербург Способ оценки тяжести инфекционного поражения цнс у детей
RU2297848C2 (ru) * 2005-05-11 2007-04-27 Александр Веньяминович Иткес Генно-инженерная конструкция vegf-ибмед (vegf-ibmed)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19704301C1 (de) * 1997-02-06 1998-03-26 Hoechst Ag Der Promotor des humanen Endoglingens und seine Verwendung für die Gentherapie
HUP9900956A2 (hu) 1998-04-09 2002-04-29 Aventis Pharma Deutschland Gmbh. Egyláncú, több antigéntkötőhely kialakítására képes molekulák, előállításuk és alkalmazásuk
DE60013586T2 (de) 1999-04-02 2005-02-03 Hisamitsu Pharmaceutical Co., Inc., Tosu Genexpressions-basensequenzen zur therapeutischen anwendung und heilmittel zur gentherapie
US20090136465A1 (en) 2007-09-28 2009-05-28 Intrexon Corporation Therapeutic Gene-Switch Constructs and Bioreactors for the Expression of Biotherapeutic Molecules, and Uses Thereof
EP2310507A4 (en) 2008-07-08 2013-03-20 David Gladstone Inst METHOD AND COMPOSITIONS FOR ANGIOGENIC MODULATION
EP2951306A4 (en) 2013-01-30 2016-07-27 Univ Nebraska COMPOSITIONS AND METHOD FOR TREATING COMPLICATIONS RELATED TO DIABETES

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5466596A (en) * 1992-08-25 1995-11-14 Mount Sinai Hospital Corporation Tissue specific transcriptional regulatory element

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506466D0 (en) * 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
DE19704301C1 (de) * 1997-02-06 1998-03-26 Hoechst Ag Der Promotor des humanen Endoglingens und seine Verwendung für die Gentherapie

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5466596A (en) * 1992-08-25 1995-11-14 Mount Sinai Hospital Corporation Tissue specific transcriptional regulatory element

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GOUGOS A., LETARTE M., J. Biol Chem., 265, № 15, р.8361-8364, 1990. *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2295281C2 (ru) * 2005-04-20 2007-03-20 Федеральное государственное учреждение Научно-исследовательский институт детских инфекций, г.Санкт-Петербург Способ оценки тяжести инфекционного поражения цнс у детей
RU2297848C2 (ru) * 2005-05-11 2007-04-27 Александр Веньяминович Иткес Генно-инженерная конструкция vegf-ибмед (vegf-ibmed)

Also Published As

Publication number Publication date
EP0857781A2 (de) 1998-08-12
JPH11178A (ja) 1999-01-06
TR199800168A2 (xx) 1998-08-21
KR19980071084A (ko) 1998-10-26
CN1196784C (zh) 2005-04-13
CA2222981A1 (en) 1998-08-06
HUP9800247A3 (en) 2002-11-28
AU736724B2 (en) 2001-08-02
CZ33298A3 (cs) 1998-08-12
US6103527A (en) 2000-08-15
HU9800247D0 (en) 1998-03-30
AU5293198A (en) 1998-08-13
HUP9800247A2 (hu) 1998-10-28
BR9800563A (pt) 1999-06-29
AR011110A1 (es) 2000-08-02
CZ289227B6 (cs) 2001-12-12
CN1203948A (zh) 1999-01-06
PL324688A1 (en) 1998-08-17
EP0857781A3 (de) 2001-05-16
DE19704301C1 (de) 1998-03-26
MX9800981A (es) 1998-08-30

Similar Documents

Publication Publication Date Title
Bivalacqua et al. Adenoviral gene transfer of endothelial nitric oxide synthase (eNOS) to the penis improves age-related erectile dysfunction in the rat
Pastorcic et al. Control of transcription initiation in vitro requires binding of a transcription factor to the distal promoter of the ovalbumin gene
US20100311161A1 (en) Method for tissue regeneration
Ranganathan et al. Cloning of murine tissue factor and regulation of gene expression by transforming growth factor type beta 1.
JP2010029207A (ja) ＨＭＧ蛋白質（ｈｉｇｈｍｏｂｉｌｉｔｙｇｒｏｕｐｐｒｏｔｅｉｎ）遺伝子の核酸配列およびそれらの使用
CA2198080A1 (en) Cell cycle regulated repressor and dna element
Gilbert et al. “Macrophage” nitric oxide synthase is a glucocorticoid‐inhibitable primary response gene in 3T3 cells
Rosati et al. Identification and characterization of murine IRAK-M
RU2198683C2 (ru) Саморегулируемый апоптоз воспалительных клеток с помощью генной терапии
EP0937104B1 (en) Endothelium specific expression regulated by epcr control elements
AU736724B2 (en) Promoter of the human endoglin gene and its use
CA2641198A1 (en) Method for treating peripheral arterial disease with zinc finger proteins
HK1017713A (en) Promoter of the human endoglin gene and its use
JP2002533113A (ja) 複数の剪断応力応答配列（ｓｓｒｅ）および目的の遺伝子を含む発現ベクター、およびその使用法
CN113215105A (zh) Elmo2过表达间充质干细胞的构建及其在骨折治疗中的应用
MXPA98000981A (en) Promoter of human endoglin gene and his
KR100419972B1 (ko) 링커 염기서열로 연결된 인간 ｖｅｇｆ의 돌연변이형동형이합체 유전자, 이를 포함하는 발현벡터, 이의형질전환체 및 단백질
AU783059C (en) Recombinant sequence, its preparation and use
Gramigni et al. An upstream negative regulatory element in human granulocyte‐macrophage colony‐stimulating factor promoter is recognised by AP1 family members
Congiu et al. The function of conserved elements in the promoter of the mouse angiotensinogen gene
JP2005312304A (ja) 新規インターフェロン制御因子活性化ポリペプチド及びそれをコードする核酸
MAŁECKI et al. Institute, Warsaw, Poland;'Department of Pharmacology, National Institute of Public
AU7164000A (en) Nucleic acid sequences of genes of the high mobility group proteins and their use
CN1467295A (zh) 一种以微生物克隆载体生产治疗血管疾病基因药物血管内皮生长因子-2裸dna的方法
PL194452B1 (pl) Wektor ekspresyjny do terapii genowej stanów niedokrwiennych, oligonukleotydowe startery oraz sposób otrzymywania wektora ekspresyjnego do terapii genowej stanów niedokrwiennych

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20060206